$CYRX

Cryoport, Inc. (CYRX): Results of Operations and Financial Condition

Cryoport, Inc. (CYRX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Cryoport Reports Second Quarter 2026 Financial Results · Second quarter revenue grew 8% year-over-year to $49.0 million · Life Sciences Services revenue increased 15% year-over-year · BioStorage/BioServices revenue grew 25% year-over-year · Supporting 779 global clin

Original reporting
Published Aug 6, 2026, 8:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 6, 2026, 8:38 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$CYRX
Bullish
medium confidence
Mentioned
$CYRX
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$CYRXBullishMed
01

Why it matters

Traders can update CYRX’s growth mix (services up, products flat) and incorporate the stated adjusted EBITDA inflection when reassessing margin trajectory and operating leverage.

02

Market read

The quarter’s revenue growth and the claim of positive adjusted EBITDA are the key new datapoints for CYRX’s near-term valuation and margin expectations.

03

What to watch

The filing references upcoming facility/network expansion and product launches, but does not quantify margin guidance or near-term capex, leaving execution risk.

Relevance 7/10Novelty 7/10Timing: filed after market close, for next-session earnings-model repricing

Background

This is Cryoport’s SEC 8-K with Exhibit 99.1 covering Q2 and H1 2026 results and operational milestones tied to its temperature-controlled supply chain for life sciences and CGT.

Company-level read

Ticker impact

$CYRXBullishMedium confidence
Context

Cryoport reported Q2 2026 revenue of $49.0M (+8% YoY) and said it achieved positive adjusted EBITDA in the quarter.

Expected impact

Likely positive bias for CYRX as traders focus on adjusted EBITDA turning positive and continued CGT-related demand.

Evidence & confidence

The filing provides concrete quarterly revenue by segment, CGT trial/support metrics, and a stated adjusted EBITDA milestone, all of which are actionable for earnings-model updates.

Market effects

Supports the CGT supply-chain services growth narrative and may lift sentiment toward temperature-controlled logistics providers.

No specific regional macro impact beyond planned facility launches in Paris and Santa Ana.

Global clinical-trial support metrics reinforce demand tied to worldwide CGT pipeline expansion.

Counterpoint

Positive adjusted EBITDA may not translate to sustainable GAAP profitability, and Life Sciences Products revenue was flat year over year.

Key entities

  • Cryoport, Inc.

    NASDAQ-listed temperature-controlled supply chain provider for life sciences and CGT; reported Q2 2026 results and adjusted EBITDA milestone.

  • Orca Bio

    Cryoport customer referenced as receiving FDA approval for TREGZI during Q2 2026.

  • Vertex Pharmaceuticals

    Cryoport customer referenced as receiving FDA supplemental approval for CASGEVY during Q2 2026.

  • Verismo Therapeutics

    Referenced as selecting Cryoport Systems’ IntegriCell cryopreservation services.

Related articles

$CYRXMedAI 8/10

Cryoport (CYRX) Q2 2026 Earnings Call Transcript

Cryoport (CYRX) reported Q2 2026 revenue of $49 million, up from prior periods, led by Life Science Services. Life Science Services revenue rose 15% year over year, with biostorage and bioservices up 25%. Support for commercial cell and gene therapy rose 9% to $9.4 million. Adjusted EBITDA turned positive at $0.4 million. Full-year 2026 revenue guidance remains $192 million to $196 million.

$BKRMedAI 8/10

Baker Hughes (BKR) Raises 2026 Guidance. But Investors Aren’t Impressed

Baker Hughes (BKR) raised its 2026 revenue and adjusted EBITDA guidance following its $13.6B acquisition of Chart Industries. The company now expects revenue of $28.5B-$30.3B and adjusted EBITDA of $4.88B-$5.48B. Despite the upgrade, shares fell as near-term margins face pressure and earnings contributions were below analyst expectations. UBS lowered its price target to $70, citing integration costs and margin concerns.

$GEVMed

GE Vernova’s (GEV) $200 Billion Backlog is Coming Sooner than Expected

GE Vernova (GEV) CEO Scott Strazik expects the company's backlog to reach $200 billion in early 2027, earlier than anticipated. The company's Q2 2026 backlog was $176 billion, up 37% YoY, with revenue growing 22% YoY to $11.1 billion. GEV raised its 2026 revenue forecast to $45.5 billion-$46.5 billion. However, the company faces risks from AI bubble concerns and weakness in its Wind business.

$PLDMed

Prologis Sees Leasing Surge, Data Centers Fuel Growth Outlook

Prologis (PLD) reports a surge in leasing, with data centers driving growth. The company has secured 1.6 GW of power capacity and completed $2B in data center starts. U.S. logistics net absorption is 66M sq ft in Q2, with a 17% lease mark-to-market. Strong markets include Sun Belt, Texas, and Southern California. PLD expects e-commerce to reach 28-30% of U.S. retail sales by 2030.

$RDDTMedAI 8/10

What Happens To Reddit Stock If Search Keeps Sending Fewer People?

Reddit (RDDT) stock is down 43% over the past year, trading near $153. Q2 2026 revenue grew 61% to $805 million, with an operating margin of 28.2%. Growth is driven by higher ad revenue per user, but search referrals are volatile. Management expects Q3 2026 revenue growth to slow to 47-49%. The company aims to improve user retention and become a destination site.